Samtal med Grandmother Madeleine och Linus Lundkvist om livets mirakel, om födslokraften som varje kvinna bär – från generation till generation – världen över. Resan startade när Linus partner valde att föda hemma. Hennes högsta önskan var att det enbart var de som skulle ta emot livets gåva: deras dotter, hemma – själva. Det här är hans berättelse. YouTube: https://youtu.be/geTlMs9TD7g
Läs mer
Månad: maj 2020
Fem projekt finansieras för innovation i vård och omsorg
Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer
Results from the global Phase II Study 22 trial testing AstraZeneca’s tremelimumab, an anti-CTLA4 antibody, added to Imfinzi (durvalumab) demonstrated promising clinical activity and tolerability in patients with advanced hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer.1
Läs mer
Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II DESTINY-Lung01 trial
Results from the ongoing Phase II DESTINY-Lung01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) achieved a clinically meaningful tumour response in patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease had progressed following one or more systemic therapies.
Läs mer
Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial
Results from the Phase II DESTINY-CRC01 trial of AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.
Läs mer
Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial
Detailed results from the positive, registrational, randomised controlled Phase II DESTINY-Gastric01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR) and overall survival (OS), a key secondary endpoint, versus chemotherapy.
Läs mer
Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial
Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
Läs mer
Presskonferens efter regionstyrelsens sammanträde
Måndag den 1 juni sammanträder regionstyrelsen i Umeå. För att berätta om styrelsens olika beslut bjuder presidiet in till en presskonferens.
Läs mer
Ett år med rökfria utomhusmiljöer i Västerbotten
Den 31 maj 2019 infördes rökfria utomhusmiljöer i Region Västerbotten. Framförallt handlar beslutet om att erbjuda en välkomnande miljö för alla men också om att uppmärksamma tobakens negativa konsekvenser både när det handlar om hälsa och miljö.
Läs mer
Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer
Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) ……
Läs mer